Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
Impacte
Scholar |
Altres documents de l'autoria: Lorenzo, Miguel; Miñana, Gema; Palau, Patricia; Amiguet, Martina; Seller, Julia; García Pinilla, José Manuel; Villar, Sandra; De la Espriella, Rafael; Núñez, Eduardo; Górriz, José Luis; Valle, Alfonso; Bodí, Vicent; Sanchis, Juan; Bayes-Genis, Antoni; Núñez, Julio; DAPA-VO2 Investigators
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONAquest recurs és restringit
https://doi.org/10.1016/j.cardfail.2023.02.008 |
Metadades
Títol
Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection FractionAutoria
Data de publicació
2023-05Editor
ElsevierISSN
1071-9164Cita bibliogràfica
Lorenzo M, Miñana G, Palau P, Amiguet M, Seller J, Garcia Pinilla JM, Domínguez E, Villar S, De la Espriella R, Núñez E, Górriz JL, Valle A, Bodí V, Sanchis J, Bayés-Genis A, Núñez J; DAPA-VO2 Investigators. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction. J Card Fail. 2023; 29(5): 849-854. doi: 10.1016/j.cardfail.2023.02.008.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
https://www.sciencedirect.com/science/article/pii/S107191642300060X?casa_token=Y ...Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Background: We aimed to evaluate the effect of dapagliflozin on short-term changes in hemoglobin in patients with stable heart failure with reduced ejection fraction (HFrEF) and whether these changes mediated the ... [+]
Background: We aimed to evaluate the effect of dapagliflozin on short-term changes in hemoglobin in patients with stable heart failure with reduced ejection fraction (HFrEF) and whether these changes mediated the effect of dapagliflozin on functional capacity, quality of life and NT-proBNP levels.
Methods: This is an exploratory analysis of a randomized, double-blinded clinical trial in which 90 stable patients with HFrEF were randomly allocated to dapagliflozin or placebo to evaluate short-term changes in peak oxygen consumption (peak VO2) (NCT04197635). This substudy evaluated 1- and 3-month changes in hemoglobin levels and whether these changes mediated the effects of dapagliflozin on peak VO2, Minnesota Living-With-Heart-Failure test (MLHFQ) and NT-proBNP levels.
Results: At baseline, mean hemoglobin levels were 14.3 ± 1.7 g/dL. Hemoglobin levels significantly increased in those taking dapagliflozin (1 month: + 0.45 g/dL (P = 0.037) and 3 months:+ 0.55 g/dL (P = 0.012)]. Changes in hemoglobin levels positively mediated the changes in peak VO2 at 3 months (59.5%; P < 0.001). Changes in hemoglobin levels significantly mediated the effect of dapagliflozin in the MLHFQ at 3 months (-53.2% and -48.7%; P = 0.017) and NT-proBNP levels at 1 and 3 months (-68.0%; P = 0.048 and -62.7%; P = 0.029, respectively).
Conclusions: In patients with stable HFrEF, dapagliflozin caused a short-term increase in hemoglobin levels, identifying patients with greater improvements in maximal functional capacity, quality of life and reduction of NT-proBNP levels. [-]
Publicat a
Journal of Cardiac Failure, 2023, vol. 29, no 5Entitat finançadora
Astra Zeneca | Unidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Institute, Spanish Clinical Research Network | CIBER Cardiovascular
Codi del projecte o subvenció
ESR-17- 13447 | PT17/0017/0003 | PT20/00100 | 16/11/00420 | 16/11/00403 | 16/11/00486
Drets d'accés
Copyright © Elsevier Inc. All rights reserved.
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
Apareix a les col.leccions
- MED_Articles [667]